Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

| More on:
Person holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be nearing a record high, but that doesn't mean there aren't big potential gains to be made.

For example, the ASX 200 share in this article, which is swimming in cash, has been tipped rise very strongly from current levels.

Which ASX 200 share?

The share in question is Neuren Pharmaceuticals Ltd (ASX: NEU). It is a biotechnology company targeting disorders of the central nervous system.

Its lead asset is Daybue (trofinetide) which has been licenced to Acadia Pharmaceuticals (NASDAQ: ACAD). It also has a number of promising products under development that could drive future growth.

Bell Potter has been pleased with the company's performance, noting that Daybue sales are in line with expectations. It said:

Overall, a positive update considering the two prior quarters were below market expectations. Daybue appears to have entered a more steady-state phase in the US following the initial surge in demand in the first few months post launch. We continue to expect modest annual US Daybue sales growth in CY25-CY26, bolstered by geographical expansion into Canada (first sales likely CY25) and Europe (first sales likely CY26).

But the big news was that the ASX 200 share has received another major cash windfall from its partner. Bell Potter highlights that this gives Neuren a significant cash balance, which is likely to increase further. It adds:

NEU will receive two US$50m (~A$76m) cash milestones in Q1 CY25 from the sale of the priority review voucher by Acadia and CY24 annual sales reaching >US$250m. Therefore, with cash balance as at 30-Sep-2024 of A$210m, plus ~A$150m in milestones to be received in 1Q CY25, we expect NEU will have >A$350m in cash as at 1Q CY25, more than enough to fund at least two Phase 3 clinical trials for NEU's second asset, not to mention ongoing royalties in CY25 and beyond.

In light of this, the broker has reaffirmed its buy rating and $25.00 price target. Based on its current share price of $16.33, this implies potential upside of 53% for investors. It concludes:

We have updated our near-term forecasts to reflect the PRV sale timing and the assumption that NEU will internally fund multiple Phase 3 trials for NNZ-2591 over the next few years. Our BUY recommendation and $25.00 PT remains unchanged. Roughly $10/share of our valuation is attributed to Daybue licensing income, hence our BUY recommendation is driven by a positive view on NNZ-2591. The next steps for NNZ-2591 are further FDA engagement on the Phase 3 design in PhelanMcDermid syndrome, likely in 1Q CY25, followed by starting the Phase 3 trial in CY25.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »